Quality of Life Is Related to Fecal Calprotectin Concentrations in Colonic Crohn Disease and Ulcerative Colitis, but not in Ileal Crohn Disease.
Quality of Life Is Related to Fecal Calprotectin Concentrations in Colonic Crohn Disease and Ulcerative Colitis, but not in Ileal Crohn Disease.
复制标题
DOI：
10.1097/md.0000000000003477
复制
发表时间：
2016-04
期刊：
影响因子：
1.6
通讯作者：
Klute L
中科院分区：
文献类型：
--
作者：
Gauss A;Geiss T;Hinz U;Schaefert R;Zwickel P;Zawierucha A;Stremmel W;Klute L
为了制定治疗目标，我们旨在确定炎症性肠病（IBD）患者粪便钙卫蛋白与健康相关生活质量之间的关系。这项回顾性单中心横断面研究纳入了已完成标准化问卷（包括健康相关生活质量（炎症性肠病简短问卷）和临床疾病活动性评分）的非卧床IBD患者，并在问卷完成后30天内提供粪便样本进行钙卫蛋白测定。在所示参数之间进行相关性分析。进行事后分析，仅考虑在问卷完成后3天内测量粪便钙卫蛋白浓度的患者的数据。197例克罗恩病患者和111例溃疡性结肠炎患者入组研究。较低的粪便钙卫蛋白浓度与较好的健康相关生活质量相关。相关性较弱，但如果仅包括问卷完成后3天内测量的粪便钙卫蛋白浓度，则相关性更强（3天的结果;克罗恩病：n = 86，rS =-0.419，P <0.001;溃疡性结肠炎：n = 43，rS =-0.432，P = 0.004）。 在克罗恩病中，粪便钙卫蛋白浓度与健康相关生活质量之间的显著相关性在结肠受累患者中发现（n = 59，rS =-0.470，P <0.001），但在单纯回肠疾病患者中没有发现（n = 27，rS =-0.268，P = 0.18）。 粪便钙卫蛋白浓度与临床疾病活动性之间的相关性也仅为弱至中度。由于其中度相关性与粪便钙卫蛋白浓度在IBD患者结肠受累，健康相关的生活质量应与其他标志物结合使用IBD管理。这在孤立性回肠克罗恩病中更为重要，因为在该疾病中，粪便钙卫蛋白浓度与健康相关生活质量之间没有显著相关性，尤其是在研究中使用时，应注意尽可能缩短IBD患者的临床评估和粪便钙卫蛋白浓度测定之间的时间。
Supplemental Digital Content is available in the text To formulate therapy goals, we aimed to define the relationship between fecal calprotectin and health-related quality of life in inflammatory bowel diseases (IBDs). This retrospective single-center cross-sectional study included ambulatory IBD patients who had completed standardized questionnaires comprising items of health-related quality of life (Short Inflammatory Bowel Disease Questionnaire) and clinical disease activity scores, and who had provided stool samples for calprotectin determination within 30 days of questionnaire completion. Correlation analyses were performed between the indicated parameters. Post hoc analysis was conducted, taking into account only data from patients with fecal calprotectin concentrations measured within 3 days of questionnaire completion. One hundred ninety-seven patients with Crohn disease and 111 patients with ulcerative colitis were enrolled in the study. Lower fecal calprotectin concentrations were associated with better health-related quality of life. The correlations were weak, but stronger if only fecal calprotectin concentrations measured within 3 days of questionnaire completion were included (results for 3 days; Crohn disease: n = 86, rS = −0.419, P < 0.001; ulcerative colitis: n = 43, rS = −0.432, P = 0.004). In Crohn disease, a significant correlation between fecal calprotectin concentration and health-related quality of life was found in patients with colonic involvement (n = 59, rS = −0.470, P < 0.001), but not in patients with purely ileal disease (n = 27, rS = −0.268, P = 0.18). Correlations between fecal calprotectin concentrations and clinical disease activity were also only weak to moderate. Owing to its moderate correlation with fecal calprotectin concentrations in IBD patients with colonic involvement, health-related quality of life should be used in combination with other markers for IBD management. This is even more important in isolated ileal Crohn disease, where no significant correlation between fecal calprotectin concentration and health-related quality of life was found. Especially for use in research studies, care should be taken to keep the time between clinical evaluation of IBD patients and the determination of fecal calprotectin concentrations as short as possible.